SUBJECT INDEX

Acetylcholine, 280
Acral erythema, 243
Adapted Symptom Distress Scale-2, 262
Advanced disease, concentration loss and, 282
Aging
  attentional functioning and, 282-283
  of skin, 240
Alertness, 280
Alopecia
  etiologic agents, 236
  nursing interventions, 236-238
  pathophysiology, 235-236
  resources, 237
  self-care guide, 298
  types, 235-236
Analgesic ladder, 294
Anorexia
  assessment, 267
  defined, 266
  interventions, 267, 268
  pathophysiology, 266-267
Antiemetics, constipation from, 291-292
Antifungal agents, for mucositis, 251
Antihistamines, for nausea, vomiting and retching, 260, 261
Attention
  aging and, 282-283
  brain mechanisms, 280
  capacity, 279
  characteristics, 279
  conserving, 284-285
  directed, 279-280, 282
  impairment. *See* Concentration loss
  processes, 279-280
  restoration interventions, 285-286

Basal layer, 240
Basement membrane, 239-240
Benadryl, 251
Benzamides, for nausea, vomiting, and retching, 260, 261
Benzodiazepines, for nausea, vomiting, and retching, 260, 261
Biologic response modifiers (BRMs), 281
Bleeding, malignant skin lesions and, 241
Body image, alopecia and, 237-238
Body mass index, 267
BRMs (biologic response modifiers), 281
Butyrophenones, for nausea, vomiting and retching, 260, 261

Cachexia, 266
  assessment, 268
  defined, 267-268
  interventions, 268
  pathophysiology, 268
Cancer-related factors, in concentration loss, 281
Cancer treatment
  concentration loss and, 281
  fatigue and, 275
Candidiasis, 249, 251
Cannabinoids, 260, 261, 268
CCSE (Cognitive Capacity Screening Examination), 283-284
Central nervous system therapy, long-term effects, 281
Chemoreceptor trigger zone (CTZ), 257
Chemotherapeutic agents
  acral erythema and, 243
  alopecia induction, 236
  emetogenic potential, 259
  mechanism of action, 248
  mucositis and, 249
  skin reactions, 242
Chemotherapy. *See also* Chemotherapeutic agents
  constipation from, 291
  and radiation skin reactions, 244
  skin changes, 241-243
Chlorhexidine, 250, 251
Chlorpromazine, 259, 260
Cognitive Capacity Screening Examination (CCSE), 283-284
Cognitive impairment, concentration loss and, 282
Colonic motility, 290-291
Concentration loss, 279
  assessment, 283-284
  etiologic factors, 280-283
  interventions, 284-286
  manifestations, 280
  v depression, 284
  v memory problems, 284
Constipation
  defined, 289
  nursing implications, 293-294
  pathophysiology, 290-291
  primary *v* secondary, 289
  treatment, 293, 294
Continence, 290
Corticosteriods, for nausea, vomiting and retching, 260, 261
Cosmetics, 237
CTZ (chemoreceptor trigger zone), 257
Cytokines, skin reactions, 243

Dakin's solution, 241
Debridement, 241
Defecation, 290
Depression, *v* attentional impairment, 284
Dermis, 240
Desquamation, 244
Dexamethasone, 260, 261, 268
Diarrhea
  assessment, 292-293
  classification, 289-290
  defined, 289
  nursing implications, 293-294
  pathophysiology, 292-293
Diazepam, 260, 261
Diphenhydramine, 260, 261
Dronabinol, 260
Droperidol, 260, 261

Dysphagia
  assessment, 269-270
  delivery, 269
  interventions, 269-270
  pathophysiology, 268-269
  transfer, 269
  transport, 269

Effort, attention and, 279
Elderly, constipation and, 289
Emetic center, 257
Enteral nutrition, self-care guide, 304-305
Epidermis, 239-240
Exercise, in fatigue treatment, 275-276

Fatigue, 272
  assessment, 276-277
  attentional, 282
  historical overview, 272-273
  influencing factors, 275
  mental, 274
  motivational, 274
  nursing care, 276-277
  pathophysiology, 273-274
  treatment, 275-276
  weakness and, 274
5-Fluorouracil, stomatitis, 250
Functional capacity measurement, 273

Gastrointestinal system, physiology, 290
Gelfoam, 241
Granisetron, 260-261, 292
Granulocyte colony-stimulating factor, 243
Granulocyte-macrophage colony-stimulating factor, 243

Hair
  growth, physiology of, 235
  loss. *See* Alopecia
  preservation, 236-237
Haloperidol, 260, 261
Heterocyclic antidepressants (HCAs), 292
Hydrogen peroxide, for mucositis, 250-251
Hydroxyzine, 260
Hyperpigmentation, 242-243
Hypersensitivity reactions, 243
Hypodynamia, 273
Hypokinesia, 273

Interieukin-2, toxicity, 243
INV-2 (Rhodes Index of Nausea and Vomiting), 258

Laxatives, 292, 293
Lorazepam, 260, 261

McCorkle's Symptom Distress Scale, 294
Megestrol acetate, 268
Memory problems, *v* attentional impairment, 284
Mesalt, 241
Metoclopramide, 260, 268
Mini Mental Status Examination (MMSE), 283-284
Mobility impairments, fatigue and, 275
Moistening agents, 251
Motility, colonic, 290-291
Mouthwashes, for mucositis, 251, 253
Mucositis
  assessment, 252
  defined, 248
  implications for practice, education, research, 253-254
  nursing diagnoses, 252-253
  oral hygiene, 253
  pathophysiology, 248-249
  prevention, 250
  risk factors, 249-250
  self-care guide, 302
  symptom experience, 249
  treatment, 250-251
  WHO grading system, 252

Nausea, vomiting, and retching (NVR), 256
  assessment, 262, 263
  background, 256
  concept dilemma, 257-258
  intervention complexities, 259
  measurement dilemma, 258
  nursing implications/challenges, 262-264
  pharmacologic interventions, 259-264
  physiologic mechanisms, 256-257
  self-care guide, 303
  self-care management, 262-264
  types, 258-259
Neuropathies, 243
Neurotoxicity, constipation and, 291
Norepinephrine, 280
NVR. *See* Nausea, vomiting, and retching (NVR)

Odor management strategies, 241
Ondansetron, 260
Opioid analgesics
  concentration loss and, 282
  constipation from, 292
Oral Assessment Guide, 252
Oral complications. *See* Mucositis; Stomatitis; Xerostomia
Oral hygiene, for mucositis, 253

Pain
  concentration loss and, 282
  control, malignant skin lesions and, 241
Patient education. *See* Self-care guide(s)
Pentoxifylline, 268
Perchlorperazine, 261
Peristalsis, 290

Pharmacotherapy
affecting colonic motility, 291
for anorexia, 267, 268
for cachexia, 268
constipation from, 291-292
for nausea, vomiting and retching, 259-264
Phenothiazines, for nausea, vomiting and retching, 259-260
Prednisolone, 268
Pre-existing conditions, fatigue and, 275
Pressure ulcers, 244-245
Promethazine, 260
Pruritus, 245

Radiation therapy
and chemotherapy skin reactions, 244
for dysphagia, 270
oral complications, 248-249
skin care, self-care guide for, 299
skin reactions, 243-244
Receptors, cutaneous, 240
Retching. *See* Nausea, vomiting, and retching (NVR)
Rhodes Adapted Symptom Distress Scale, 294
Rhodes Index of Nausea and Vomiting (INV-2), 258

Saliva substitutes, 251
Scalp hypothermia, for hair preservation, 236-237
SCJ (self-care journal), 262
Self-care guide(s)
for alopecia, 298
for enteral nutrition, 304-305
for mucositis, stomatitis, and xerostomia, 302
for nausea, vomiting, and retching, 303
for skin care during radiation therapy, 299
for skin impairment, 300-301
Self-care journal (SCJ), 262
Self-report questionnaires, for nausea, vomiting, and retching, 258
Serotonin, 257
Serotonin antagonists, for nausea, vomiting, and retching, 260-261
Serotonin receptor, 257
Sialogogues, 252
Signs, *v* symptoms, 232
Situational demands, fatigue and, 275
Skin
aging, 240
anatomy, 239-240
cancer-related changes, 239
chemotherapy-radiation reactions, 244
color, changes in, 242-243
functions, 239-240
impairment, self-care guide for, 300-301
malignant lesions, 240-241
physiology, 239-240
pressure ulcers, 244-245
problems, nursing management of, 245
radiation reactions, 243-244
during radiation therapy, self-care guide for, 299
therapy-related changes, 241-245
Stomatitis
defined, 248
implications for practice, education, research, 253-254
pathophysiology, 248-249
prevention, 250
risk factors, 249-250
self-care guide, 302
symptom experience, 249
Sucralfate, 250, 251
Swallowing
difficulty. *See* Dysphagia
therapy, 270
Symptom distress, 232
Symptom experience, 232-233. *See also specific symptoms*
Symptom management, 231-232. *See also specific symptoms*
Symptom occurrence, 232
Symptoms, *v* signs, 232

Thiethylperazine, 260
Thrush, chronic, 249
Touch sensation, changes, 243

Ultraviolet radiation, skin and, 240

Visual analogue scale (VAS), 258
Vomiting. *See* Nausea, vomiting, and retching (NVR)

Weakness, 272
assessment, 276-277
fatigue and, 274
historical overview, 272-273
influencing factors, 275
nursing care, 276-277
pathophysiology, 273-274
treatment, 276
Winningham's Psychobiological-Entropy Model, 273, 274
World Health Organization (WHO)
analgesic ladder, 294
mucositis grading system, 252

Xerostomia
defined, 248
implications for practice, education, research, 253-254
pathophysiology, 248-249
prevention, 250
risk factors, 249-250
self-care guide, 302
symptom experience, 249
treatment, 251-252

1995 AUTHOR INDEX

Almadrones, L., 194

Brant, J.M., 203

Campana, P., 194
Camp-Sorrell, D., 153, 167, 213
Cimprich, B., 279
Cohen, M.Z., 59

Dantis, E.C., 194
Dean, G., 17
Devesa, S.S., 78
Donnelly, E., 3
Dose, A.M., 248

Eick-Swigart, J., 42

Ferrell, B.R., 17
Fife, B.L., 1

Galassi, A., 77
Gallagher, J., 239
Germino, B.B., 43
Grant, M.M., 266

Haberman, M., 23
Hassey Dow, K., 128
Hymovich, D.P., 51

Ingle, R.J., 184

Jenkins, J., 77
Johnson, M.H., 256, 298

Kagawa-Singer, M., 109
Kahn, D.L., 9

Lamb, M.A., 120

McCabe, M.S., 137
McDaniel, R.W., 231, 232, 256, 298
McDermott, M.K., 221
Mager Stellman, J., 103
Mahon, S.M., 88

Nail, L.M., 272

O'Connor, A.P., 68

Pickard-Holley, S.K., 235

Rapsilber, L.M., 213
Rhodes, V.A., 231, 232, 256, 298
Richardson, D.K., 174
Rivera, L.M., 266
Rumsey, K.A., 174

Steeves, R.H., 9
Stellman, S.D., 103

Taylor, E.J., 1, 32
Thomas, S.L., 289
Trammell, L., 167

Winningham, M.L., 272
Winslow, M.N., 167
Woods, N.F., 143
Wright, P.S., 289